X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC LTD DIVIS LABORATORIES/
ALEMBIC LTD
 
P/E (TTM) x 33.5 58.1 57.7% View Chart
P/BV x 5.4 3.3 165.9% View Chart
Dividend Yield % 0.9 0.3 266.3%  

Financials

 DIVIS LABORATORIES   ALEMBIC LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ALEMBIC LTD
Mar-16
DIVIS LABORATORIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,22253 2,314.4%   
Low Rs78429 2,675.8%   
Sales per share (Unadj.) Rs153.14.7 3,243.8%  
Earnings per share (Unadj.) Rs39.98.8 455.3%  
Cash flow per share (Unadj.) Rs44.69.0 495.3%  
Dividends per share (Unadj.) Rs10.000.15 6,666.7%  
Dividend yield (eoy) %1.00.4 272.8%  
Book value per share (Unadj.) Rs201.827.7 727.8%  
Shares outstanding (eoy) m265.47267.03 99.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.68.7 75.3%   
Avg P/E ratio x25.14.7 536.7%  
P/CF ratio (eoy) x22.54.6 493.3%  
Price / Book Value ratio x5.01.5 335.7%  
Dividend payout %25.01.7 1,464.3%   
Avg Mkt Cap Rs m266,26610,962 2,429.1%   
No. of employees `0009.7NA-   
Total wages/salary Rs m4,687238 1,969.5%   
Avg. sales/employee Rs Th4,175.0NM-  
Avg. wages/employee Rs Th481.5NM-  
Avg. net profit/employee Rs Th1,089.3NM-  
INCOME DATA
Net Sales Rs m40,6431,260 3,224.9%  
Other income Rs m749264 283.9%   
Total revenues Rs m41,3921,524 2,715.9%   
Gross profit Rs m14,46083 17,464.3%  
Depreciation Rs m1,23361 2,008.6%   
Interest Rs m230 7,533.3%   
Profit before tax Rs m13,953285 4,897.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m3,3496 54,904.8%   
Profit after tax Rs m10,6042,343 452.6%  
Gross profit margin %35.66.6 541.5%  
Effective tax rate %24.02.1 1,121.0%   
Net profit margin %26.1185.9 14.0%  
BALANCE SHEET DATA
Current assets Rs m40,1051,689 2,374.8%   
Current liabilities Rs m6,595486 1,356.3%   
Net working cap to sales %82.595.4 86.4%  
Current ratio x6.13.5 175.1%  
Inventory Days Days119217 54.6%  
Debtors Days Days8181 99.6%  
Net fixed assets Rs m19,9951,624 1,231.1%   
Share capital Rs m531534 99.4%   
"Free" reserves Rs m53,0435,960 890.0%   
Net worth Rs m53,5747,404 723.6%   
Long term debt Rs m0104 0.0%   
Total assets Rs m61,5858,010 768.8%  
Interest coverage x618.4950.7 65.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.2 419.5%   
Return on assets %17.329.3 59.0%  
Return on equity %19.831.6 62.6%  
Return on capital %26.131.3 83.4%  
Exports to sales %02.9 0.0%   
Imports to sales %25.228.9 87.5%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs m10,259364 2,820.9%   
Fx inflow Rs m35,38437 95,374.3%   
Fx outflow Rs m10,399365 2,849.4%   
Net fx Rs m24,985-328 -7,621.1%   
CASH FLOW
From Operations Rs m11,493346 3,325.5%  
From Investments Rs m-11,372-48 23,889.9%  
From Financial Activity Rs m-93-301 30.9%  
Net Cashflow Rs m28-3 -946.7%  

Share Holding

Indian Promoters % 52.0 64.0 81.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 5,900.0%  
FIIs % 19.0 9.7 195.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 26.1 65.9%  
Shareholders   31,796 54,701 58.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES SHASUN LTD  ELDER PHARMA  TORRENT PHARMA  AUROBINDO PHARMA  CIPLA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 18, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS